Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.74 |
| ▸ | PPARA | Q07869 | 8/20 | 0.74 |
| ▸ | PPARD | Q03181 | 5/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6004633 | 0.91 | PPARG (0.72) | PPARGPPARAPPARDCACNA1BCACNA1H | |
| SCHEMBL5345508 | 0.91 | PPARG (0.72) | PPARGPPARAPPARDCACNA1BCACNA1H | |
| SCHEMBL7517998 | 0.89 | PPARG (0.66) | PPARGPPARAPPARDCACNA1BCACNA1H | |
| SCHEMBL7928584 | 0.88 | PPARG (0.81) | PPARGPPARAPPARD | |
| SCHEMBL6002510 | 0.88 | PPARG (0.77) | PPARGPPARA | |
| Ragaglitazar SCHEMBL682732 | 0.86 | PPARA (1.00) | PPARGPPARAPPARD | |
| Ragaglitazar SCHEMBL29369224 | 0.86 | PPARA (1.00) | PPARGPPARAPPARD | |
| Ragaglitazar SCHEMBL676872 | 0.86 | PPARA (1.00) | PPARGPPARAPPARD | |
| Ragaglitazar SCHEMBL4822459 | 0.86 | PPARA (1.00) | PPARGPPARAPPARD | |
| SCHEMBL6002537 | 0.84 | PPARG (0.85) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002542237-A | — | — | 2002-12-10 | — | — | JP | claimed |
| US-20020128260-A1 | Useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR); fused ring derivatives of malonic acid, ester or amides | JEPPESEN LONE (DK) | 2002-09-12 | — | — | US | claimed |
| US-6369055-B1 | TREATMENT OF CONDITIONS MEDIATED BY NUCLEAR RECEPTORS, IN PARTICULAR THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR); LOWERING BOTH HYPERTRIGLYCERIDEMIA AND HYPERGLYCEMIA, 2-(4-(2-PHENOXAZINE-10-YL-ETHOXY)-BENZYL)-MALONIC ACID | NOVO NORDISK A/S (DK) | 2002-04-09 | — | — | US | claimed |
| EP-1171431-A1 | COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2002-01-16 | — | — | EP | claimed |
| WO-2000063190-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-10-26 | — | — | WO | claimed |
| US-20020128260-A1 | Useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR); fused ring derivatives of malonic acid, ester or amides | JEPPESEN LONE (DK) | 2002-09-12 | — | — | US | disclosed |
| US-6369055-B1 | TREATMENT OF CONDITIONS MEDIATED BY NUCLEAR RECEPTORS, IN PARTICULAR THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR); LOWERING BOTH HYPERTRIGLYCERIDEMIA AND HYPERGLYCEMIA, 2-(4-(2-PHENOXAZINE-10-YL-ETHOXY)-BENZYL)-MALONIC ACID | NOVO NORDISK A/S (DK) | 2002-04-09 | — | — | US | disclosed |
| EP-1171431-A1 | COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000063190-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128260-A1 | Useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR); fused ring derivatives of malonic acid, ester or amides | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.